首页> Journal of neurology, neurosurgery, and psychiatry> Association of age and inflammatory disease activity in the pivotal natalizumab clinical trials in relapsing-remitting multiple sclerosis.

Association of age and inflammatory disease activity in the pivotal natalizumab clinical trials in relapsing-remitting multiple sclerosis.

导出 LinkOut

翻译打印收藏纠错

第一作者： Eva M,Strijbis

第一单位： Department of Neurology, MS Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, The Netherlands e.strijbis@amsterdamumc.nl.

作者： Eva M,Strijbis ^[1] ; Eline,Coerver ^[2] ; Jop,Mostert ^[3] ; Zoé L E,van Kempen ^[2] ; Joep,Killestein ^[2] ; Jacynthe,Comtois ^[4] ; Pavle,Repovic ^[5] ; James D,Bowen ^[5] ; Gary,Cutter ^[6] ; Marcus,Koch ^[7]

作者单位： Department of Neurology, MS Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, The Netherlands e.strijbis@amsterdamumc.nl. ^[1] Department of Neurology, MS Center Amsterdam, Amsterdam University Medical Centers, Amsterdam, The Netherlands. ^[2] Department of Neurology, Rijnstate Hospital Arnhem, Arnhem, The Netherlands. ^[3] Department of Medicine, Neurology service, Maisonneuve-Rosemont Hospital, Montreal, Québec, Canada. ^[4] Multiple Sclerosis Center, Swedish Neuroscience Institute, Seattle, Washington, USA. ^[5] Department of Biostatistics, University of Alabama at Birmingham, Birmingham, Alabama, USA. ^[6] Department of Clinical Neurosciences, University of Calgary, Calgary, Alberta, Canada.;Department of Community Health Sciences, University of Calgary, Calgary, Alberta, Canada. ^[7]

关键词 MRI MULTIPLE SCLEROSIS